Lakewood Amedex Biotherapeutics Inc (LABT)

Jun 12, 2026

Lakewood-Amedex Biotherapeutics Company Profile & Introduction - Moomoo

Jun 12, 2026

Jun 12, 2026

LABT Price Today: Lakewood-Amedex Biotherapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC

Jun 12, 2026

Jun 12, 2026

Lakewood-Amedex Biotherapeutics (LABT) Stock Price, News & Analysis $LABT - MarketBeat

Jun 12, 2026

Jun 03, 2026

Lakewood-Amedex Biotherapeutics (LABT) Stock Trends and Sentiment 2026 $LABT - MarketBeat

Jun 03, 2026

Jun 02, 2026

Lakewood-Amedex stock falls despite positive Nu-3 manufacturing update - MSN

Jun 02, 2026

May 29, 2026

Meet Lakewood-Amedex Biotherapeutics: Fly exclusive with CEO Kelvin Cooper - TipRanks

May 29, 2026

May 29, 2026

Lakewood-Amedex Biotherapeutics(LABT) Stock Options Chain | Quotes & News - Moomoo

May 29, 2026

May 28, 2026

Lakewood-Amedex selects PERI as CRO for Nu-3 phase 2 trial - Investing.com Nigeria

May 28, 2026

May 27, 2026

Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers - GuruFocus

May 27, 2026

May 27, 2026

Lakewood-Amedex Biotherapeutics issued two new patents - TipRanks

May 27, 2026

May 27, 2026

Lakewood-Amedex receives patents in Australia, New Zealand By Investing.com - Investing.com South Africa

May 27, 2026

May 27, 2026

Lakewood-Amedex receives patents in Australia, New Zealand - Investing.com Australia

May 27, 2026

May 26, 2026

Lakewood-Amedex (LABT) posts Q1 loss, closes Series C for ~$7.5M - Stock Titan

May 26, 2026

May 26, 2026

LABT - Finviz

May 26, 2026

May 26, 2026

Lakewood-Amedex (LABT) registers 9,375,000 shares after $7.5M Series C raise - Stock Titan

May 26, 2026

May 23, 2026

Lakewood-Amedex Biotherapeutics Inc. Reports Q1 2026 Financial Results and Advances in Antimicrobial Therapy Development - minichart.com.sg

May 23, 2026

May 22, 2026

Lakewood-Amedex Biotherapeutics Inc. 1Q 2026: Revenue ($886.75K), EPS ($0.2) — 10-Q Summary - TradingView

May 22, 2026

May 22, 2026

Lakewood-Amedex (LABT) logs $0.9M loss, raises $7.5M and still faces going concern risk - Stock Titan

May 22, 2026

May 20, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

May 20, 2026

May 19, 2026

Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) AI-Powered Stock Analysis - Meyka

May 19, 2026

May 19, 2026

Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers - Sahm

May 19, 2026

May 19, 2026

Lakewood-Amedex Stock Falls Despite Positive Nu-3 Manufacturing Update - Sahm

May 19, 2026

May 18, 2026

Lakewood-Amedex Biotherapeutics advances production of foot ulcer candidate Nu3 - TipRanks

May 18, 2026

May 18, 2026

Positive Nu-3 Data Advances Lakewood-Amedex Toward Phase 2 Diabetic Foot Ulcer Trial (LABT) - Yahoo Finance

May 18, 2026

May 18, 2026

Lakewood-Amedex completes manufacturing steps for Nu-3 trial By Investing.com - Investing.com South Africa

May 18, 2026

May 18, 2026

LABT Stock Slides As Volatility Grips Biotech Micro-Cap - StocksToTrade

May 18, 2026

May 18, 2026

Lakewood-Amedex Provides Progress Update Of Nu-3 In Diabetic Foot Ulcers; Stock Down - RTTNews

May 18, 2026

May 18, 2026

Lakewood-Amedex Biotherapeutics Announces Positive Data For The Advancement Of Lead Candidate, Nu-3 - TradingView

May 18, 2026

May 18, 2026

LABT Stock Slides As Volatility Tests Biotech Day Traders - timothysykes.com

May 18, 2026

May 18, 2026

Lakewood-Amedex completes manufacturing steps for Nu-3 trial - Investing.com

May 18, 2026

May 17, 2026

Lakewood-Amedex jumps 20% in Nasdaq market debut - MSN

May 17, 2026

May 15, 2026

LABT Should I Buy - Intellectia AI

May 15, 2026

May 14, 2026

Lakewood‑Amedex (LABT) registers 9.65M shares tied to Series C conversion - Stock Titan

May 14, 2026

May 14, 2026

[EFFECT] Lakewood-Amedex Biotherapeutics Inc. SEC Filing - Stock Titan

May 14, 2026

May 14, 2026

LABT Stock Price, Quote & Chart | LAKEWOOD-AMEDEX BIOTHERAPEUT (NASDAQ:LABT) - ChartMill

May 14, 2026

May 12, 2026

Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to - GuruFocus

May 12, 2026

May 12, 2026

Lakewood-Amedex selects PERI as CRO for Nu-3 phase 2 trial By Investing.com - Investing.com South Africa

May 12, 2026

May 12, 2026

Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3 - PR Newswire

May 12, 2026